• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

地诺单抗停药后发生严重自发性椎体骨折：三例病例报告

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.

作者信息

Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O

机构信息

Center of Bone Diseases, Bone and Joint Department, Lausanne University Hospital, Av. Pierre-Decker 4, 1011, Lausanne, Switzerland.

出版信息

Osteoporos Int. 2016 May;27(5):1923-5. doi: 10.1007/s00198-015-3380-y. Epub 2015 Oct 28.

DOI:10.1007/s00198-015-3380-y
PMID:26510845
Abstract

Osteoporosis treatments are usually given for a limited period of time in order to balance benefits and risks. We report three cases of postmenopausal women without any previous fragility fracture who presented severe spontaneous vertebral fractures after denosumab discontinuation. We think that the occurrence of these fractures could be explained by the severe rebound effect observed after denosumab discontinuation and that a consensus regarding the end of treatment with denosumab has to be defined.

摘要

骨质疏松症治疗通常在有限的时间段内进行，以平衡获益与风险。我们报告了3例绝经后女性病例，她们既往无脆性骨折史，在停用地诺单抗后出现了严重的自发性椎体骨折。我们认为这些骨折的发生可能是由于停用 地诺单抗后观察到的严重反跳效应所致，并且必须就停止使用地诺单抗治疗达成共识。

相似文献

1
Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.地诺单抗停药后发生严重自发性椎体骨折：三例病例报告
Osteoporos Int. 2016 May;27(5):1923-5. doi: 10.1007/s00198-015-3380-y. Epub 2015 Oct 28.
2
Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.地诺单抗停药后严重的反弹相关椎体骨折：9例临床病例报告
J Clin Endocrinol Metab. 2017 Feb 1;102(2):354-358. doi: 10.1210/jc.2016-3170.
3
Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.地舒单抗停药后应用阿仑膦酸钠对既往接受过双膦酸盐治疗的女性预防自发性多发椎体骨折无效：两例报告。
Osteoporos Int. 2019 May;30(5):1111-1115. doi: 10.1007/s00198-018-04820-8. Epub 2019 Jan 6.
4
Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.地舒单抗治疗颌骨炎停药后与反跳相关的椎体骨折。
Osteoporos Int. 2018 Mar;29(3):769-772. doi: 10.1007/s00198-017-4334-3. Epub 2017 Dec 11.
5
Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.地诺单抗停用后与反弹相关的椎体骨折——来自临床和生物力学研究
Osteoporos Int. 2016 May;27(5):1917-21. doi: 10.1007/s00198-015-3458-6. Epub 2015 Dec 22.
6
Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).绝经后日本骨质疏松症女性和男性接受三年地诺单抗治疗：地诺单抗骨折干预随机安慰剂对照试验（DIRECT）1年开放标签扩展研究的结果
Osteoporos Int. 2015 Feb;26(2):765-74. doi: 10.1007/s00198-014-2964-2. Epub 2014 Nov 18.
7
[Multiple vertebral fractures after denosumab discontinuation].[地诺单抗停药后多发性椎体骨折]
Ugeskr Laeger. 2018 Nov 5;180(45).
8
Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.长期停用地舒单抗治疗后显著的骨丢失：FREEDOM 研究后。
Osteoporos Int. 2018 Jan;29(1):41-47. doi: 10.1007/s00198-017-4242-6. Epub 2017 Oct 3.
9
Clinical vertebral fractures following denosumab discontinuation.狄诺塞麦停药后发生的临床椎体骨折。
Endocrine. 2016 Oct;54(1):271-272. doi: 10.1007/s12020-016-1030-6. Epub 2016 Jul 8.
10
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.地诺单抗治疗绝经后骨质疏松症女性8年或5年的效果：FREEDOM扩展研究结果
Osteoporos Int. 2015 Dec;26(12):2773-83. doi: 10.1007/s00198-015-3234-7. Epub 2015 Jul 23.

引用本文的文献

1
Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II study.抗RANKL单克隆抗体narlumosbart治疗绝经后骨质疏松症女性的疗效和安全性：一项多中心、随机、双盲、安慰剂和活性药物对照的II期研究
EClinicalMedicine. 2025 Jul 4;85:103329. doi: 10.1016/j.eclinm.2025.103329. eCollection 2025 Jul.
2
Mouse model of anti-RANKL discontinuation reveals reduced bone mass and quality through disruption of bone remodeling.抗RANKL停药小鼠模型显示，通过破坏骨重塑，骨量和骨质量降低。
Bone Res. 2025 May 28;13(1):56. doi: 10.1038/s41413-025-00433-0.
3

本文引用的文献

1
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.地诺单抗治疗绝经后骨质疏松症女性8年或5年的效果：FREEDOM扩展研究结果
Osteoporos Int. 2015 Dec;26(12):2773-83. doi: 10.1007/s00198-015-3234-7. Epub 2015 Jul 23.
2
How long should we treat?我们应该治疗多久？
Osteoporos Int. 2014 Jun;25(6):1659-66. doi: 10.1007/s00198-013-2433-3. Epub 2014 Mar 26.
3
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
Risk assessment and drug interruption guidelines for dentoalveolar surgery in patients with osteoporosis receiving anti-resorptive therapy.
接受抗吸收治疗的骨质疏松症患者牙槽外科手术的风险评估与药物中断指南
J Dent Sci. 2025 Apr;20(2):729-740. doi: 10.1016/j.jds.2025.02.002. Epub 2025 Feb 11.
4
Siglec-15 as a potential molecule involved in osteoclast differentiation and bone metabolism.唾液酸结合免疫球蛋白样凝集素15作为一种参与破骨细胞分化和骨代谢的潜在分子。
Heliyon. 2024 Oct 1;10(21):e38537. doi: 10.1016/j.heliyon.2024.e38537. eCollection 2024 Nov 15.
5
The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation.地诺单抗对绝经后女性破骨细胞前体的影响：停药后过冲现象的一种可能解释。
J Bone Miner Res. 2025 Mar 15;40(3):301-306. doi: 10.1093/jbmr/zjae170.
6
Biologic Antiresorptive: Denosumab.生物抗吸收剂：地诺单抗。
Indian J Orthop. 2023 Dec 10;57(Suppl 1):127-134. doi: 10.1007/s43465-023-01064-5. eCollection 2023 Dec.
7
Mechanisms and Treatment Options for Hyperthyroid-Induced Osteoporosis: A Narrative Review.甲状腺功能亢进症所致骨质疏松症的发病机制与治疗选择：一篇叙述性综述
Cureus. 2023 Nov 14;15(11):e48798. doi: 10.7759/cureus.48798. eCollection 2023 Nov.
8
Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab.骨质疏松性椎体骨折患者与停用地诺单抗后出现反弹相关椎体骨折患者的管理异同
J Clin Med. 2023 Sep 10;12(18):5874. doi: 10.3390/jcm12185874.
9
Trabecular bone deterioration in a postmenopausal female suffering multiple spontaneous vertebral fractures due to a delayed denosumab injection - A post-treatment re-initiation bone biopsy-based case study.因地诺单抗注射延迟导致多发性自发性椎体骨折的绝经后女性小梁骨恶化——一项基于治疗后重新开始的骨活检的病例研究。
Bone Rep. 2023 Jul 22;19:101703. doi: 10.1016/j.bonr.2023.101703. eCollection 2023 Dec.
10
Long-term and sequential treatment for osteoporosis.骨质疏松症的长期和序贯治疗。
Nat Rev Endocrinol. 2023 Sep;19(9):520-533. doi: 10.1038/s41574-023-00866-9. Epub 2023 Jul 18.
绝经激素治疗与妇女健康倡议随机试验干预和停药后扩展阶段的健康结局。
JAMA. 2013 Oct 2;310(13):1353-68. doi: 10.1001/jama.2013.278040.
4
Global consensus statement on menopausal hormone therapy.全球绝经期激素治疗共识声明。
Climacteric. 2013 Apr;16(2):203-4. doi: 10.3109/13697137.2013.771520.
5
Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial.地诺单抗停用与相关骨折发生率：来自骨质疏松症中地诺单抗每6个月降低骨折评估（FREEDOM）试验的分析。
J Bone Miner Res. 2013 Apr;28(4):746-52. doi: 10.1002/jbmr.1808.
6
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.地舒单抗对骨密度和骨转换生化标志物的影响：一项 2 期临床试验 8 年结果。
Osteoporos Int. 2013 Jan;24(1):227-35. doi: 10.1007/s00198-012-2052-4. Epub 2012 Jul 10.
7
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).唑来膦酸治疗骨质疏松症 3 年与 6 年的疗效：一项针对 HORIZON-关键性骨折试验（PFT）的随机扩展研究。
J Bone Miner Res. 2012 Feb;27(2):243-54. doi: 10.1002/jbmr.1494.
8
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.绝经后子宫切除妇女停用结合型马雌激素后的健康结局：一项随机对照试验。
JAMA. 2011 Apr 6;305(13):1305-14. doi: 10.1001/jama.2011.382.
9
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.地舒单抗治疗及其停药对低骨量绝经后妇女骨密度和骨转换标志物的影响。
J Clin Endocrinol Metab. 2011 Apr;96(4):972-80. doi: 10.1210/jc.2010-1502. Epub 2011 Feb 2.
10
Fracture risk remains reduced one year after discontinuation of risedronate.停用利塞膦酸盐一年后，骨折风险仍会降低。
Osteoporos Int. 2008 Mar;19(3):365-72. doi: 10.1007/s00198-007-0460-7. Epub 2007 Oct 16.